Advances in Radiation Therapy for Anal Cancer

Abstract

Given its rarity and prognostic heterogeneity, improving outcomes for anal cancer can be challenging. Since the seminal Nigro study in the 1970s, chemoradiation has become standard of care, curing a large portion of patients and avoiding morbidity of an abdominoperineal resection. More advanced disease has a poorer prognosis and response rate. Radiation protocols, focusing on optimal dosing/fractionation and the integration of chemotherapy agents, are evolving. Modern techniques such as intensity-modulated radiation therapy have further reduced toxicities to improve patient outcomes. Despite these technological advancements, long-term toxicities, including bowel, urinary, and sexual dysfunction, remain significant issues. Ongoing clinical trials, such as the ACT II and PLATO trials, are redefining dose escalation and de-escalation protocols for both early- and late-stage tumors, balancing efficacy with quality of life. As we move toward personalized approaches to anal cancer treatment, this review highlights the importance of multidisciplinary care and ongoing research in optimizing chemoradiotherapy regimens, minimizing side effects, and enhancing survival outcomes for this challenging rare malignancy.

Keywords

anal squamous cell carcinoma - chemoradiotherapy - HPV-associated malignancy - quality of life - precision medicine

Authors' Contribution

All authors were involved with the conception and design, writing, and final approval of this study.

Publication History

Received: 19 January 2025

Accepted: 27 February 2025

Article published online:
20 May 2025

• References

• 1 Cancer of the Anus, Anal Canal, and Anorectum - Cancer Stat Facts. SEER. . Accessed August 20, 2024 at: https://seer.cancer.gov/statfacts/html/anus.html
• 2 Cruz A, Chen D, Hsu P. et al. Racial and gender disparities in the incidence of anal cancer: analysis of the Nationwide Inpatient Sample (NIS). J Gastrointest Oncol 2019; 10 (01) 37-41
• 3 Islami F, Ferlay J, Lortet-Tieulent J, Bray F, Jemal A. International trends in anal cancer incidence rates. Int J Epidemiol 2017; 46 (03) 924-938
• 4 Hoff PM, Coudry R, Moniz CMV. Pathology of anal cancer. Surg Oncol Clin N Am 2017; 26 (01) 57-71
• 5 Lukovic J, Kim JJ, Krzyzanowska M, Chadi SA, Taniguchi CM, Hosni A. Anal adenocarcinoma: a rare malignancy in need of multidisciplinary management. JCO Oncol Pract 2020; 16 (10) 635-640
• 6 Nigro ND, Vaitkevicius VK, Considine Jr B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974; 17 (03) 354-356
• 7 Lin C, Franceschi S, Clifford GM. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. Lancet Infect Dis 2018; 18 (02) 198-206
• 8 Cancer Facts & Figures 2024. Accessed August 20, 2024 at: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2024-cancer-facts-figures.html
• 9 Wei F, Gaisa MM, D'Souza G. et al. Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. Lancet HIV 2021; 8 (09) e531-e543
• 10 Sun G, Dong X, Tang X, Qu H, Zhang H, Zhao E. The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: a meta-analysis. Oncotarget 2017; 9 (08) 8081-8088
• 11 Kabarriti R, Brodin NP, Ohri N. et al. Human papillomavirus, radiation dose and survival of patients with anal cancer. Acta Oncol 2019; 58 (12) 1745-1751
• 12 Morris VK, Xiao W, Holliday EB. et al. Time dependency for HPV ctDNA detection as a prognostic biomarker for anal cancer. JCO 2024; 42 (16, Suppl): 3513-3513
• 13 Kabarriti R, Lloyd S, Jabalee J. et al. Evaluating tumor tissue modified viral (TTMV)-HPV DNA for the early detection of anal squamous cell carcinoma recurrence. Cancers (Basel) 2025; 17 (02) 174
• 14 Gilbert DC, Wakeham K, Langley RE, Vale CL. Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis. Br J Cancer 2019; 120 (02) 256-268
• 15 Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370 (9581) 59-67
• 16 Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis - ScienceDirect. Accessed August 21, 2024 at: https://www-sciencedirect-com.laneproxy.stanford.edu/science/article/pii/S2352301819304345?via%3Dihub
• 17 Albuquerque A, Stirrup O, Nathan M, Clifford GM. Burden of anal squamous cell carcinoma, squamous intraepithelial lesions and HPV16 infection in solid organ transplant recipients: a systematic review and meta-analysis. Am J Transplant 2020; 20 (12) 3520-3528
• 18 Daling JR, Madeleine MM, Johnson LG. et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101 (02) 270-280
• 19 Duncan KC, Chan KJ, Chiu CG. et al. HAART slows progression to anal cancer in HIV-infected MSM. AIDS 2015; 29 (03) 305-311
• 20 Hotca A, Goodman KA. Trends in anal cancer: leveraging public health efforts to improve cancer care. J Clin Oncol 2023; 41 (06) 1180-1182
• 21 What Is Anal Cancer? | Types of Anal Cancer. Accessed January 27, 2025 at: https://www.cancer.org/cancer/types/anal-cancer/about/what-is-anal-cancer.html
• 22 Holliday EB, Lester SC, Harmsen WS. et al. Extended-field chemoradiation therapy for definitive treatment of anal canal squamous cell carcinoma involving the para-aortic lymph nodes. Int J Radiat Oncol Biol Phys 2018; 102 (01) 102-108
• 23 Perry WB, Connaughton JC. Abdominoperineal resection: how is it done and what are the results?. Clin Colon Rectal Surg 2007; 20 (03) 213-220
• 24 Schraut WH, Wang CH, Dawson PJ, Block GE. Depth of invasion, location, and size of cancer of the anus dictate operative treatment. Cancer 1983; 51 (07) 1291-1296
• 25 Boman BM, Moertel CG, O'Connell MJ. et al. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer 1984; 54 (01) 114-125
• 26 Fernández-Martínez D, Rodríguez-Infante A, Otero-Díez JL, Baldonedo-Cernuda RF, Mosteiro-Díaz MP, García-Flórez LJ. Is my life going to change?-a review of quality of life after rectal resection. J Gastrointest Oncol 2020; 11 (01) 91-101
• 27 Nigro ND. An evaluation of combined therapy for squamous cell cancer of the anal canal. Dis Colon Rectum 1984; 27 (12) 763-766
• 28 Martenson JA, Lipsitz SR, Lefkopoulou M. et al. Results of combined modality therapy for patients with anal cancer (E7283). An Eastern Cooperative Oncology Group study. Cancer 1995; 76 (10) 1731-1736
• 29 Sischy B, Doggett RL, Krall JM. et al. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314. J Natl Cancer Inst 1989; 81 (11) 850-856
• 30 Doci R, Zucali R, La Monica G. et al. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol 1996; 14 (12) 3121-3125
• 31 Gerard JP, Ayzac L, Hun D. et al. Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients. Radiother Oncol 1998; 46 (03) 249-256
• 32 Peiffert D, Seitz JF, Rougier P. et al. Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study. Ann Oncol 1997; 8 (06) 575-581
• 33 Martenson JA, Lipsitz SR, Wagner Jr H. et al. Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study. Int J Radiat Oncol Biol Phys 1996; 35 (04) 745-749
• 34 John M, Pajak T, Flam M. et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am 1996; 2 (04) 205-211
• 35 Ben-Josef E, Moughan J, Ajani JA. et al. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol 2010; 28 (34) 5061-5066
• 36 Glynne-Jones R, Meadows HM, Lopes A, Muirhead R, Sebag-Montefiore D, Adams R. ACTII Study Group. Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial. Ann Oncol 2020; 31 (10) 1376-1385
• 37 Gilroy JS, Amdur RJ, Louis DA, Li JG, Mendenhall WM. Irradiating the groin nodes without breaking a leg: a comparison of techniques for groin node irradiation. Med Dosim 2004; 29 (04) 258-264
• 38 Blinde SE, Schasfoort R, Mens JW, Verhoef C, Olofsen M, Nuyttens JJ. Inguinal lymph node recurrence in the untreated groin of patients with anal carcinoma. Dis Colon Rectum 2014; 57 (05) 578-584
• 39 Kachnic LA, Winter KA, Myerson RJ. et al. Long-term outcomes of NRG oncology/RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in anal canal cancer. Int J Radiat Oncol Biol Phys 2022; 112 (01) 146-157
• 40 Lee NY, Lu JJ, Yu Y. eds. Target Volume Delineation and Field Setup: A Practical Guide for Conformal and Intensity-Modulated Radiation Therapy. 2nd ed.. Springer; 2022
• 41 Ajani JA, Winter KA, Gunderson LL. et al. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol 2009; 27 (07) 1116-1121
• 42 Ajani JA, Winter KA, Gunderson LL. et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008; 299 (16) 1914-1921
• 43 Kachnic LA, Winter K, Myerson RJ. et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013; 86 (01) 27-33
• 44 Muirhead R, Drinkwater K, O'Cathail SM. et al. Initial results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015. Clin Oncol (R Coll Radiol) 2017; 29 (03) 188-197
• 45 Possiel J, Ammon HE, Guhlich M. et al. Volumetric modulated arc therapy improves outcomes in definitive radiochemotherapy for anal cancer whilst reducing acute toxicities and increasing treatment compliance. Cancers (Basel) 2021; 13 (11) 2533 . Published 2021 May 21.
• 46 Kachnic LA, Tsai HK, Coen JJ. et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 2012; 82 (01) 153-158
• 47 Vendrely V, Lemanski C, Pommier P. et al; For FFCD Investigators/Collaborators. Treatment, outcome, and prognostic factors in non-metastatic anal cancer: the French nationwide cohort study FFCD-ANABASE. Radiother Oncol 2023; 183: 109542
• 48 Bartelink H, Roelofsen F, Eschwege F. et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15 (05) 2040-2049
• 49 UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 1996; 348 (9034) 1049-1054
• 50 Northover J, Glynne-Jones R, Sebag-Montefiore D. et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010; 102 (07) 1123-1128
• 51 Flam M, John M, Pajak TF. et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14 (09) 2527-2539
• 52 James RD, Glynne-Jones R, Meadows HM. et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol 2013; 14 (06) 516-524
• 53 Hung A, Crane C, Delclos M. et al. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer 2003; 97 (05) 1195-1202
• 54 Gunderson LL, Winter KA, Ajani JA. et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 2012; 30 (35) 4344-4351
• 55 Peiffert D, Tournier-Rangeard L, Gérard JP. et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 2012; 30 (16) 1941-1948
• 56 Goodman KA, Julie D, Cercek A. et al. Capecitabine with mitomycin reduces acute hematologic toxicity and treatment delays in patients undergoing definitive chemoradiation using intensity modulated radiation therapy for anal cancer. Int J Radiat Oncol Biol Phys 2017; 98 (05) 1087-1095
• 57 Glynne-Jones R, Meadows H, Wan S. et al; National Cancer Research Institute Anal Sub Group and Colorectal Clinical Oncology Group. EXTRA – a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys 2008; 72 (01) 119-126
• 58 Meulendijks D, Dewit L, Tomasoa NB. et al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer 2014; 111 (09) 1726-1733
• 59 Allegra CJ, Yothers G, O'Connell MJ. et al. Final results from NSABP protocol R-04: neoadjuvant chemoradiation (RT) comparing continuous infusion (CIV) 5-FU with capecitabine (Cape) with or without oxaliplatin (Ox) in patients with stage II and III rectal cancer. JCO 2014; 32 (15, Suppl): 3603-3603
• 60 Hofheinz RD, Wenz F, Post S. et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012; 13 (06) 579-588
• 61 Muirhead R, Partridge M, Hawkins MA. A tumor control probability model for anal squamous cell carcinoma. Radiother Oncol 2015; 116 (02) 192-196
• 62 Treatment Clinical Trials for Anal Cancer - NCI. June 13, 2017. Accessed October 19, 2024 at: https://www.cancer.gov/research/participate/clinical-trials/disease/anal-cancer/treatment
• 63 Sebag-Montefiore D, Adams R, Bell S. et al. The Development of an Umbrella Trial (PLATO) to address radiation therapy dose questions in the locoregional management of squamous cell carcinoma of the anus. Int J Radiat Oncol Biol Phys 2016; 96 (02) E164-E165
• 64 Leichman L, Nigro N, Vaitkevicius VK. et al. Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am J Med 1985; 78 (02) 211-215
• 65 Gilbert A, McParland L, Webster J. et al. Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5). Ann Oncol 2019; 30: v203-v204
• 66 Buchberger D, Kreinbrink P, Kharofa J. Proton therapy in the treatment of anal cancer in pelvic kidney transplant recipients: a case series. Int J Part Ther 2019; 6 (01) 28-34
• 67 Wo JY, Plastaras JP, Metz JM. et al. Pencil beam scanning proton beam chemoradiation therapy with 5-fluorouracil and mitomycin-C for definitive treatment of carcinoma of the anal canal: a multi-institutional pilot feasibility study. Int J Radiat Oncol Biol Phys 2019; 105 (01) 90-95
• 68 Kharofa J. A Prospective Pilot Study to Evaluate the Feasibility of Intensity Modulated Proton Therapy in Reducing Toxicity in Anal Cancer. clinicaltrials.gov; 2024 . Accessed October 19, 2024 at: https://clinicaltrials.gov/study/NCT03018418
• 69 M.D. Anderson Cancer Center. Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: A Feasibility Trial. clinicaltrials.gov; 2023 . Accessed October 19, 2024 at: https://clinicaltrials.gov/study/NCT03690921
• 70 Dale JE, Sebjørnsen S, Leh S. et al. Multimodal therapy is feasible in elderly anal cancer patients. Acta Oncol 2017; 56 (01) 81-87
• 71 National Cancer Institute. Guidelines for the use of proton radiation therapy in NCI-sponsored cooperative group clinical trials. Accessed March 9, 2025 at: https://www.rtog.org/LinkClick.aspx?fileticket=x6bzrIf2Th8%253D%26tabid=184
• 72 Bailleux C, Zwarthoed C, Evesque L. et al. Prognostic impact of post-treatment FDG PET/CT in anal canal cancer: a prospective study. Radiother Oncol 2023; 188: 109905
• 73 Glynne-Jones R, Sebag-Montefiore D, Meadows HM. et al; ACT II Study Group. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol 2017; 18 (03) 347-356
• 74 de Meric de Bellefon M, Lemanski C, Castan F. et al. Long-term follow-up experience in anal canal cancer treated with intensity-modulated radiation therapy: clinical outcomes, patterns of relapse and predictors of failure. Radiother Oncol 2020; 144: 141-147
• 75 Kouzy R, Abi Jaoude J, Lin D. et al. Patient-reported GI outcomes in patients with anal cancer receiving modern chemoradiation. JCO Oncol Pract 2020; 16 (12) e1524-e1531
• 76 Mitra D, Hong TS, Horick N. et al. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. Adv Radiat Oncol 2017; 2 (02) 110-117
• 77 Bentzen AG, Guren MG, Vonen B. et al. Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort. Radiother Oncol 2013; 108 (01) 55-60
• 78 Mirabeau-Beale K, Hong TS, Niemierko A. et al. Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer. Pract Radiat Oncol 2015; 5 (03) e113-e118
• 79 Sunesen KG, Nørgaard M, Lundby L. et al. Long-term anorectal, urinary and sexual dysfunction causing distress after radiotherapy for anal cancer: a Danish multicentre cross-sectional questionnaire study. Colorectal Dis 2015; 17 (11) O230-O239
• 80 Knowles G, Haigh R, McLean C, Phillips H. Late effects and quality of life after chemo-radiation for the treatment of anal cancer. Eur J Oncol Nurs 2015; 19 (05) 479-485
• 81 Jephcott CR, Paltiel C, Hay J. Quality of life after non-surgical treatment of anal carcinoma: a case control study of long-term survivors. Clin Oncol (R Coll Radiol) 2004; 16 (08) 530-535
• 82 Goodman KA, Riedel E, Tom A. et al. Prospective study of vaginal dilator use following pelvic radiation therapy for gastrointestinal malignancies. Int J Radiat Oncol Biol Phys 2013; 87 (02) S75
• 83 Kirchheiner K, Zaharie A, Smet S. et al; EMBRACE Collaborative Group. Association between the regular use of vaginal dilators and/or sexual activity and vaginal morbidity in locally advanced cervical cancer survivors: an EMBRACE-I Study Report. Int J Radiat Oncol Biol Phys 2025; 121 (02) 452-464
• 84 Arzola A, Chang E, Rooney MK. et al. Daily vaginal dilator use during radiation for women with squamous cell carcinoma of the anus: vaginal wall dosimetry and patient-reported sexual function. Pract Radiat Oncol 2024; 14 (02) e105-e116
• 85 Briere TM, Crane CH, Beddar S. et al. Reproducibility and genital sparing with a vaginal dilator used for female anal cancer patients. Radiother Oncol 2012; 104 (02) 161-166